Form 4: Agenus Inc. CEO Garo Armen Receives Stock in Lieu of Cash as Part of Compensation

Agenus Inc. CEO Garo Armen received 22,136 shares of common stock as part of his compensation in lieu of cash, according to a recent SEC filing.

Summary

• Garo H. Armen, CEO of Agenus Inc., received 22,136 shares of Agenus Inc. common stock on March 8, 2024, as part of his compensation in lieu of cash.
• The shares were issued under the Amended and Restated Agenus Inc. 2019 Equity Incentive Plan and were fully vested on the date of issuance.
• The price of the common stock on March 8, 2024, was $0.67 per share.
• Following the transaction, Dr. Armen directly owns 1,275,465 shares, indirectly owns 625,969 shares through IRA accounts, and indirectly owns 579,000 shares as trustee and general partner.
• Dr. Armen disclaims beneficial ownership to the extent of his pecuniary interest in shares held by Pixie Partners.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of executive compensation. The acceptance of stock in lieu of cash could be seen as a positive sign of confidence, but it's not definitively bullish.

Positives

• The CEO's acceptance of stock in lieu of cash may signal confidence in the company's future performance.
• The shares are fully vested on the date of issuance, aligning the CEO's interests with those of the shareholders.

Industry Context

This type of compensation arrangement, where executives receive stock in lieu of cash, is not uncommon in the biotechnology industry, particularly for companies that are focused on conserving cash or aligning executive incentives with shareholder value.

Comparison to Industry Standards

• Stock-based compensation is a common practice among publicly traded companies, especially in the biotech sector.
• Comparing the percentage of equity granted to Garo Armen relative to his total compensation package with that of CEOs at similarly sized biotech firms (e.g., Iovance Biotherapeutics, Gritstone Bio) could provide insights into whether this arrangement is standard or unusual.
• Benchmarking the vesting schedule of these shares against industry norms would also be relevant.

Stakeholder Impact

• Shareholders may view the CEO's acceptance of stock in lieu of cash as a positive sign, aligning his interests with theirs.
• Employees may see this as a sign of the company's commitment to conserving cash.

Key Dates